To Get Full Access :

NCE-1 Intelligence & Market Opportunity

Lynavoy

Linerixibat
Ileal Bile Acid Transporter (IBAT) Inhibitor
Oral Tablet

Lynavoy (linerixibat) is a prescription medication used in adults to treat cholestatic pruritus associated with primary biliary cholangitis (PBC), a chronic liver disease marked by bile acid buildup and persistent itching.

Unlike conventional symptomatic treatments, Lynavoy works by inhibiting the ileal bile acid transporter (IBAT) in the intestine, reducing bile acid reabsorption and promoting their elimination. This helps lower circulating bile acid levels and directly targets the cause of itching.

Cholestatic pruritus can significantly impact sleep, daily functioning, and overall quality of life. With targeted therapies like Lynavoy, patients can experience meaningful relief and improved comfort.

Lynavoy is taken orally and is intended for ongoing management under medical supervision.

Approval Date
17-Mar-26
NCE-1 Date
17-Mar-30
NCE Date
17-Mar-31
Commercial snapshot

Market performance & projections

Revenue ($M)
NA
CAGR (%)
NA
Projected sales, 2026–2032 ($M)
Analyst projection, $M per year
2026
32
2027
62
2028
123
2029
167
2030
214
2031
258
2032
300
Molecule profile

Details & specifications

Molecule
Linerixibat
Innovator
GLAXOSMITHKLINE LLC
Dosage Form
Oral Tablet
Strength
40 mg
Therapeutic Category
Ileal Bile Acid Transporter (IBAT) Inhibitor
Usage
To treat cholestatic pruritus associated with primary biliary cholangitis
Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data
Milestones tracked against primary FDA sources and refreshed continuously.
Analyst-built projections
Seven-year sales outlooks modeled by our pharma intelligence team.
First-to-file focus
Exclusivity windows framed around the decisions generics teams actually make.
Partnership on demand
From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?